NSEI:JAGSNPHARM

Stock Analysis Report

Executive Summary

Jagsonpal Pharmaceuticals Limited develops and manufactures active pharmaceutical ingredients (APIs) and formulations.

Snowflake

Fundamentals

Flawless balance sheet and undervalued.

Share Price & News

How has Jagsonpal Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.4%

JAGSNPHARM

3.9%

IN Pharmaceuticals

3.9%

IN Market


1 Year Return

-13.5%

JAGSNPHARM

-17.5%

IN Pharmaceuticals

6.0%

IN Market

Return vs Industry: JAGSNPHARM exceeded the Indian Pharmaceuticals industry which returned -17.5% over the past year.

Return vs Market: JAGSNPHARM underperformed the Indian Market which returned 6% over the past year.


Shareholder returns

JAGSNPHARMIndustryMarket
7 Day0.4%3.9%3.9%
30 Day-6.8%-2.4%7.8%
90 Day2.8%-1.7%2.5%
1 Year-12.6%-13.5%-16.8%-17.5%8.2%6.0%
3 Year-39.4%-40.3%-25.5%-27.0%23.0%16.7%
5 Year13.6%11.1%-10.6%-13.3%43.5%30.0%

Price Volatility Vs. Market

How volatile is Jagsonpal Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Jagsonpal Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: JAGSNPHARM (₹24.1) is trading below our estimate of fair value (₹173.24)

Significantly Undervalued: JAGSNPHARM is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: JAGSNPHARM is good value based on its PE Ratio (7.5x) compared to the Pharmaceuticals industry average (15.7x).

PE vs Market: JAGSNPHARM is good value based on its PE Ratio (7.5x) compared to the Indian market (13.3x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate JAGSNPHARM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: JAGSNPHARM is good value based on its PB Ratio (0.6x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Jagsonpal Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: JAGSNPHARM's forecast earnings growth (18.9% per year) is above the savings rate (7.6%).

Earnings vs Market: JAGSNPHARM's earnings (18.9% per year) are forecast to grow faster than the Indian market (18.2% per year).

High Growth Earnings: JAGSNPHARM's earnings are forecast to grow, but not significantly.

Revenue vs Market: Insufficient data to determine if JAGSNPHARM's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if JAGSNPHARM's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if JAGSNPHARM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Jagsonpal Pharmaceuticals performed over the past 5 years?

-5.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: JAGSNPHARM's earnings have declined by -5.6% per year over the past 5 years.

Accelerating Growth: JAGSNPHARM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: JAGSNPHARM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.4%).


Return on Equity

High ROE: JAGSNPHARM's Return on Equity (8.1%) is considered low.


Return on Assets

ROA vs Industry: JAGSNPHARM's Return on Assets is below or equal to the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: JAGSNPHARM's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Jagsonpal Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: JAGSNPHARM's short term assets (₹975.6M) exceeds its short term liabilities (₹281.9M)

Long Term Liabilities: JAGSNPHARM's short term assets (975.6M) exceeds its long term liabilities (31.2M)


Debt to Equity History and Analysis

Debt Level: JAGSNPHARM's debt to equity ratio (3.6%) is considered satisfactory

Reducing Debt: JAGSNPHARM's debt to equity ratio has reduced from 36.5% to 3.6% over the past 5 years.

Debt Coverage: JAGSNPHARM's debt is well covered by operating cash flow (816.2%).

Interest Coverage: JAGSNPHARM's interest payments on its debt are well covered by EBIT (13.4x coverage).


Balance Sheet

Inventory Level: JAGSNPHARM has a high level of physical assets or inventory.

Debt Coverage by Assets: JAGSNPHARM's debt is covered by short term assets (assets are 25.772250x debt).


Next Steps

Dividend

What is Jagsonpal Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.04%

Current Dividend Yield


Dividend Yield vs Market

company1.0%marketbottom25%0.6%markettop25%2.4%industryaverage0.9%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: JAGSNPHARM's dividend (1.04%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: JAGSNPHARM's dividend (1.04%) is low compared to the top 25% of dividend payers in the Indian market (2.42%).

Stable Dividend: JAGSNPHARM's dividend payments have been volatile in the past 10 years.

Growing Dividend: JAGSNPHARM's dividend payments have not increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (7.8%), JAGSNPHARM's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Jagsonpal Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

6.6yrs

Average board tenure


CEO

Rajpal P. Kochhar (64yo)

11.5yrs

Tenure

0

Mr. Rajpal P. Singh Kochhar has been the Managing Director of JAGSONPAL Pharmaceuticals Ltd. since April 1, 2008 and serves as its Chairman of the Board. He studied M.Sc. in Pharmacy. 


Board Age and Tenure

6.6yrs

Average Tenure

64yo

Average Age

Experienced Board: JAGSNPHARM's board of directors are considered experienced (6.6 years average tenure).


Insider Trading

Insider Buying: JAGSNPHARM insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buy₹17,07124 Sep 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares694
Max Price₹24.60
Buy₹36,91320 Sep 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares1,503
Max Price₹24.56
Buy₹219,86328 Jun 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares8,635
Max Price₹25.60
Buy₹25,14126 Jun 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares984
Max Price₹25.55
Buy₹40,26124 Jun 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares1,573
Max Price₹25.60
Buy₹223,06603 Apr 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares8,414
Max Price₹26.61
Buy₹414,40931 Jan 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares13,695
Max Price₹30.38
Buy₹61,06325 Jan 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares1,946
Max Price₹31.38
Buy₹99,30524 Jan 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares3,170
Max Price₹31.33
Buy₹387,94523 Jan 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares12,499
Max Price₹31.05
Buy₹3109 Jan 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares1
Max Price₹31.00
Buy₹38,16405 Jan 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares1,226
Max Price₹31.13
Buy₹80,27904 Jan 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares2,579
Max Price₹31.13
Buy₹34,48903 Jan 19
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares1,108
Max Price₹31.13
Buy₹240,13827 Dec 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares7,899
Max Price₹30.48
Buy₹374,21525 Dec 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares12,257
Max Price₹30.60
Buy₹357,18922 Dec 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares11,680
Max Price₹30.59
Buy₹236,77921 Dec 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares7,751
Max Price₹30.62
Buy₹280,92108 Dec 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares10,089
Max Price₹27.85
Buy₹1,31306 Dec 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares48
Max Price₹27.36
Buy₹15,04103 Nov 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares535
Max Price₹28.15
Buy₹260,42702 Nov 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares9,264
Max Price₹28.11
Buy₹2830 Oct 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares1
Max Price₹28.05
Buy₹247,42027 Oct 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares8,812
Max Price₹28.08
Buy₹102,46726 Oct 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares3,653
Max Price₹28.10
Buy₹127,82325 Oct 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares4,556
Max Price₹28.07
Buy₹368,49724 Oct 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares13,137
Max Price₹28.06
Buy₹126,07423 Oct 18
Rajpal P. Kochhar
EntityIndividual
Role
Chief Executive Officer
Chairman & MD
Shares4,508
Max Price₹28.10

Ownership Breakdown


Management Team

  • Sanjiv Dudeja

    Chief Financial Officer

    • Tenure: 0yrs
  • Rajpal P. Kochhar (64yo)

    Chairman & MD

    • Tenure: 11.5yrs
  • Prithipal Kochhar (40yo)

    Vice President of International Business and International Marketing

    • Tenure: 8yrs
    • Compensation: ₹1.56m
  • Nandita Singh

    Company Secretary & Compliance Officer

    • Tenure: 0yrs
  • Bharat Chugh

    Assistant General Manager of Human Resources

    • Tenure: 0yrs

Board Members

  • Rajpal P. Kochhar (64yo)

    Chairman & MD

    • Tenure: 11.5yrs
  • Bharat Sinh (63yo)

    Independent Director

    • Tenure: 6.6yrs
    • Compensation: ₹250.00k
  • Ishpal Ghai (71yo)

    Independent Director

    • Tenure: 6.6yrs
    • Compensation: ₹250.00k
  • Jasbir Kochhar

    Non Executive Woman Director

    • Tenure: 4.6yrs

Company Information

Jagsonpal Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Jagsonpal Pharmaceuticals Limited
  • Ticker: JAGSNPHARM
  • Exchange: NSEI
  • Founded: 1964
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹631.372m
  • Shares outstanding: 26.20m
  • Website: https://www.jagsonpal.com

Location

  • Jagsonpal Pharmaceuticals Limited
  • T-210J, Shahpur Jat
  • New Delhi
  • Delhi
  • 110049
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
507789BSE (Mumbai Stock Exchange)YesEquity SharesININRMar 2000
JAGSNPHARMNSEI (National Stock Exchange of India)YesEquity SharesININRMar 2000

Biography

Jagsonpal Pharmaceuticals Limited develops and manufactures active pharmaceutical ingredients (APIs) and formulations. Its APIs include allylestrenol, dextropropoxyphene HCL, dextropropoxyphene napsylate,  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 12:40
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.